In Vitro Diagnostic Industry in China - Clinical Chemistry XXII

5. Summary

At present, the upstream raw materials of biochemical reagents mainly rely on imports. For the long-term development of the industry, the preparation technology of raw materials must be mastered. The domestic listed companies have a large amount of cash flow, which can provide a solid support for the independent innovation. They have money to not only invest in R&D, but also to purchase core technologies, excellent enterprises and core supply chain of raw materials, etc., to achieve the accelerated improvement of the own strength. The performance of domestic biochemical instruments still needs to be improved. In the future, it is necessary to improve the sample storage capacity, detection versatility and detection efficiency. Biochemical diagnostic instruments will develop in the direction of automation, modularization and cascading. The large-scale automated assembly lines will be an important goal for the domestic biochemical enterprises to move towards the high end.

In addition, the enterprises should actively deploy the establishment of industry standards, the construction of a reference laboratory, FDA certification, etc., to enhance the enterprises’ comprehensive competitiveness. With the accelerated entry of capital and the continuous integration and acceleration of mergers and acquisitions in the domestic biochemical diagnostic industry chain, a large number of products with domestic substitution capabilities will emerge.

Last: In Vitro Diagnostic Industry in China - Clinical Chemistry XX​I